Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk

Phase 3 Recruiting 6150 enrolled Population Health Research Institute

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The Low dose ColchicinE in pAtients with peripheral Artery DiseasE to address residual vascular Risk (LEADER-PAD) trial will evaluate if anti-inflammatory therapy with colchicine will reduce vascular events in patients with symptomatic peripheral artery disease.

Timeline

Start: 2021-05-06
Primary completion: 2029-12
Completion: 2029-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Colchicine	Small molecule	0.5 mg	Oral

Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk

Summary

Timeline

Drugs

Indications